Physician

Stephen Tiley, D.O.

According to 2025 Medicare claims, Stephen Tiley, D.O. (NPI: 1245425966) practices hematology/oncology in the Savannah, GA market, with the plurality of this provider's patient population coming from Chatham, GA. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 31404-6220.

Tiley's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 596 traditional Medicare patients, billed 19,923 HCPCS/CPT codes, and received $385,744 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 940 prescription claims across 236 beneficiaries totaling $2,210,621 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 38 claims. Open Payments data shows 6 records totaling $124. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $66,221 to $385,744. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,081,849 and ending at $2,210,621. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,696 and ending at $2,261.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	275	1,150	$66,221
2016	299	1,142	$64,670
2017	318	1,228	$71,909
2018	320	1,325	$81,785
2019	366	1,553	$99,380
2020	310	927	$57,242
2021	216	889	$81,931
2022	311	1,056	$94,267
2023	393	1,188	$106,000
2024	596	19,923	$385,744

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	191	1,395	$1,081,849
2016	239	1,776	$1,826,866
2017	217	1,328	$1,755,482
2018	217	1,651	$2,834,325
2019	228	1,653	$3,009,832
2020	215	1,370	$3,008,586
2021	142	533	$428,039
2022	138	579	$762,652
2023	235	1,028	$1,928,900
2024	236	940	$2,210,621

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	35	$23,020
2016	23	81	$40,760
2017	N/R	105	$21,853
2018	N/R	58	$9,036
2019	N/R	93	$10,031
2020	N/R	37	$3,376
2021	N/R	17	$2,472
2022	N/R	32	$1,057
2023	N/R	20	$17,568
2024	N/R	38	$997

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	212	393	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	221	263	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	210	357	$12
36415	Insertion of needle into vein for collection of blood sample	185	248	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	169	245	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	13	390	$315,307
Venclexta	Venetoclax	19	570	$294,411
Kisqali	Ribociclib Succinate	11	308	$193,650
Revlimid	Lenalidomide	12	336	$190,216
Opdivo	Nivolumab	12	336	$181,254

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$627
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$124	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Stephen Tiley, D.O.?

Tedicare shows public-source Medicare data for Stephen Tiley, D.O. (NPI 1245425966), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stephen Tiley, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Stephen Tiley, D.O.?

Stephen Tiley, D.O. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Stephen Tiley, D.O. have Open Payments data?

Stephen Tiley, D.O. has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.